- Home
- PVL vs OVID Comparison
PVL vs OVID Comparison
Compare PVL & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PVL | OVID |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.7M | 365.5M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | PVL | OVID |
|---|---|---|
| Price | $1.87 | $2.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.20 |
| AVG Volume (30 Days) | 109.6K | ★ 3.7M |
| Earning Date | 03-20-2026 | 05-12-2026 |
| Dividend Yield | ★ 7.55% | N/A |
| EPS Growth | N/A | ★ 3.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,252,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $22.53 |
| P/E Ratio | $26.85 | ★ N/A |
| Revenue Growth | N/A | ★ 1181.27 |
| 52 Week Low | $1.30 | $0.24 |
| 52 Week High | $2.04 | $2.72 |
Technical Indicators
Market Signals| Indicator | PVL | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 57.37 | 65.73 |
| Support Level | $1.73 | $1.31 |
| Resistance Level | $2.02 | $2.72 |
| Average True Range (ATR) | 0.06 | 0.22 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 38.89 | 75.00 |
Price Performance
Historical ComparisonAbout PVL Permianville Royalty Trust Trust Units
Permianville Royalty Trust is a statutory trust which holds net profits interests in the profits from the sale of oil and natural gas production from non-operated assets of both conventional properties in the States of Texas, Louisiana, and New Mexico as well as unconventional assets in the Permian and Haynesville basins.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.